Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang

MT Newswires Live

7 hours ago

Tempest Therapeutics (TPST) signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.

The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.

Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.

The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.

Tempest shares rose 35% in after-hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/2667627808"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667627808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667627808?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667627808","market":"hk","top_or_hot":-1,"title":"Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang","media":"MT Newswires Live","content":"<html><body><p> Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TPST) signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.</p><p>The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.</p><p>Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.</p><p>The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.</p><p>Tempest shares rose 35% in after-hours trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-16 05:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TPST) signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.</p><p>The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.</p><p>Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.</p><p>The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.</p><p>Tempest shares rose 35% in after-hours trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TPST","symbol_name":"Tempest Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667627808","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667627808","pubTimestamp":1789508730,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempest Therapeutics  signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.Tempest shares rose 35% in after-hours trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TPST":"Tempest Therapeutics Inc.","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","BK4539":"次新股"},"translate_title":"Tempest Therapeutics 获得森朗新体内 CAR-T 技术许可选择权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"TPST":1},"content_text":"Tempest Therapeutics (TPST) signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.Tempest shares rose 35% in after-hours trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}